Paclitaxel Treatment Options

A collection of 2030 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Home

All Treatments

Paclitaxel

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Study of Vemurafenib, Carboplatin, and Paclitaxel

NCT01636622

Completed

The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with carboplatin and paclitaxel patients with advanced cancer. The safety of the study drug combination will also be studied. Vemurafenib is designed to block a protein (called mutated BRAF) that is only found in moles (spots) of the skin and certain types of cancer cells. This drug may slow the growth of or kill these cells. Carboplatin is designed to slow the growth... Read More

Gender:

ALL

Ages:

12 years and above

Trial Updated:

06/18/2020

Locations: University of Texas MD Anderson Cancer Center, Houston, Texas

Conditions: Advanced Cancers

Learn More ›

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

NCT01285609

Completed

The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/16/2020

Locations: Sharp Memorial Hospital, San Diego, California +289 locations

Sharp Memorial Hospital, San Diego, California

Va Connecticut Healthcare System, West Haven, Connecticut

Lynn Cancer Institute Center For Hematology-Oncology, Boca Raton, Florida

Integrated Community Oncology Network, Jacksonville, Florida

University Of Illinois At Chicago Medical Center, Chicago, Illinois

Quincy Medical Group, Quincy, Illinois

Presence Medical Group Hematology Oncology, Skokie, Illinois

Southern Illinois University School Of Medicine, Springfield, Illinois

St. Francis Hospital & Health Centers, Indianapolis, Indiana

Floyd Memorial Cancer Center Of Indiana, New Albany, Indiana

Kentucky Cancer Clinic, Hazard, Kentucky

Norton Cancer Institute, Louisville, Kentucky

Montgomery Cancer Center, Mount Sterling, Kentucky

St Joseph Mercy Hospital, Ypsilanti, Michigan

University Of Kansas Cancer Center, Kansas City, Missouri

Washington University School Of Medicine, Saint Louis, Missouri

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Clinical Research Alliance, Inc., Lake Success, New York

Durham Va Medical Center (111g), Durham, North Carolina

Carolina Biooncology Institute, Huntersville, North Carolina

Novant Health Oncology Specialists, Lexington, North Carolina

Gabrail Cancer Center Research, Canton, Ohio

Oklahoma Oncology And Hematology, Pc Dba, Tulsa, Oklahoma

Kaiser Permanente Northwest Region, Portland, Oregon

Guthrie Medical Group, P.C., Sayre, Pennsylvania

Wjb Dorn Va Medical Center, Columbia, South Carolina

Cancer Center Of The Carolinas, Greenville, South Carolina

Associated in Oncology and Hematology, Chattanooga, Tennessee

Tennessee Cancer Specialists, Knoxville, Tennessee

Thompson Oncology Group, Knoxville, Tennessee

Texas Oncology, PA - South Austin Cancer Center, Austin, Texas

Blue Ridge Cancer Care, Blacksburg, Virginia

Wisconsin Institutes for Medical Research, Madison, Wisconsin

Local Institution, Quilmes, Buenos Aires

Local Institution, Rosario, Santa FE

Local Institution, San Miguel De Tucuman, Tucuman

Local Institution, Cordoba, Not set

Local Institution, Mendoza, Not set

Local Institution, Santa Fe, Not set

Local Institution, Bedford Park, South Australia

Local Institution, Box Hill, Victoria

Local Institution, Frankston, Victoria

Local Institution, Heidelberg, Victoria

Local Institution, Wodonga, Victoria

Local Institution, Graz, Not set

Local Institution, Linz, Not set

Local Institution, Salzburg, Not set

Local Institution, Aalst, Not set

Local Institution, Liege, Not set

Local Institution, Sint Niklaas, Not set

Local Institution, Yvoir, Not set

Local Institution, Fortaleza, Ceara

Local Institution, Belo Horizonte, Minas Gerais

Local Institution, Curitiba, Parana

Local Institution, Passo Fundo, RIO Grande DO SUL

Local Institution, Barretos, SAO Paulo

Local Institution, Sao Jose dos Campos, SAO Paulo

Local Institution, Porto Alegre, Not set

Local Institution, Ribeirao Preto, Not set

Local Institution, Rio de Janeiro, Not set

Local Institution, Sao Paulo, Not set

Local Institution, Montreal, Quebec

Local Institution, Oshawa, Not set

Local Institution, Santiago, Metropolitana

Local Institution, Vina Del Mar, Valparaiso

Local Institution, Guangzhou, Guangdong

Local Institution, Guanzhou, Guangdong

Local Institution, Shantou, Guangdong

Local Institution, Wuhan, Hubei

Local Institution, Nanjing, Jiangsu

Local Institution, Suzhou, Jiangsu

Local Institution, Changchun, Jilin

Local Institution, Xi'an, Shaanxi

Local Institution, Urumqi, Xinjiang

Local Institution, Hangzhou, Zhejiang

Local Institution, Beijing, Not set

Local Institution, Santiago, Not set

Local Institution, Shanghai, Not set

Local Institution, Monteria, Cordoba

Local Institution, Pereira, Risaralda

Local Institution, Ostrava, Poruba

Local Institution, Prague 2, Not set

Local Institution, Praha 5, Not set

Local Institution, Praha 8, Not set

Local Institution, Pribram V-Zdabor, Not set

Local Institution, Usti Nad Labem, Not set

Local Institution, Znojmo, Not set

Local Institution, Aalborg, Not set

Local Institution, Herlev, Not set

Local Institution, Hillerod, Not set

Local Institution, Naestved, Not set

Local Institution, Odense, Not set

Local Institution, Caen Cedex 05, Not set

Local Institution, Marseille Cedex 20, Not set

Local Institution, Paris, Not set

Local Institution, Poitiers, Not set

Local Institution, Rennes Cedex 9, Not set

Local Institution, Toulouse Cedex 9, Not set

Local Institution, Vandoeuvre-les-nancy, Not set

Local Institution, Bad Berka, Not set

Local Institution, Bochum, Not set

Local Institution, Darmstadt, Not set

Local Institution, Dresden, Not set

Local Institution, Frankfurt Am Main, Not set

Local Institution, Gauting, Not set

Local Institution, Grosshandsdorf, Not set

Local Institution, Hamburg, Not set

Local Institution, Heidelberg, Not set

Local Institution, Kassel, Not set

Local Institution, Lubeck, Not set

Local Institution, Mainz, Not set

Local Institution, Muenchen, Not set

Local Institution, Neumunster, Not set

Local Institution, Nuernberg, Not set

Local Institution, Regensburg, Not set

Local Institution, Tuebingen, Not set

Local Institution, Ulm, Not set

Local Institution, Villingen-Schwenningen, Not set

Local Institution, Hong Kong, Not set

Local Institution, New Territories, Not set

Local Institution, Budapest, Not set

Local Institution, Deszk, Not set

Local Institution, Farkasgyepu, Not set

Local Institution, Gyula, Not set

Local Institution, Matrahaza, Not set

Local Institution, Nyiregyhaza, Not set

Local Institution, Pecs, Not set

Local Institution, Sopron, Not set

Local Institution, Szekesfehervar, Not set

Local Institution, Szolnok, Not set

Local Institution, Dublin, Not set

Local Institution, Galway, Not set

Local Institution, Beer Sheva, Not set

Local Institution, Haifa, Not set

Local Institution, Jerusalem, Not set

Local Institution, Nahariya, Not set

Local Institution, Petah-Tikva, Not set

Local Institution, Rehovot, Not set

Local Institution, Tel Aviv, Not set

Local Institution, Tel-aviv, Not set

Local Institution, Tel-hashomer, Not set

Local Institution, Zerifin, Not set

Local Institution, Benevento, Not set

Local Institution, Bologna, Not set

Local Institution, Lido Di Camaiore, Not set

Local Institution, Lucca, Not set

Local Institution, Monza, Not set

Local Institution, Padova, Not set

Local Institution, Perugia, Not set

Local Institution, Siena, Not set

Local Institution, Sondrio, Not set

Local Institution, Terni, Not set

Local Institution, Treviglio, Not set

Local Institution, Nagoya-shi, Aichi

Local Institution, Nagoya, Aichi

Local Institution, Kashiwa, Chiba

Local Institution, Kanazawa-shi, Ishikawa

Local Institution, Yokohama-Shi, Kanagawa

Local Institution, Yokohama-shi, Kanagawa

Local Institution, Natori-shi, Miyagi

Local Institution, Sendai, Miyagi

Local Institution, Kurashiki-shi, Okayama

Local Institution, Hirakata-shi, Osaka

Local Institution, Osaka-shi, Osaka

Local Institution, Sunto-gun, Shizuoka

Local Institution, Chuo-ku, Tokyo

Local Institution, Ube-shi, Yamaguchi

Local Institution, Akashi, Hyogo, Not set

Local Institution, Fukuoka, Not set

Local Institution, Matsuyama, Ehime, Not set

Local Institution, Osakasayama-city, Not set

Local Institution, Sapporo Hokkaido, Not set

Local Institution, Sapporo, Hokkaido, Not set

Local Institution, Sendai, Miyagi, Not set

Local Institution, Takatsuki, Not set

Local Institution, Tokyo, Not set

Local Institution, Cheonju-si, Chungcheongbuk-do

Local Institution, Goyang-si, Gyeonggi-do

Local Institution, Suwon-si, Gyeonggi-do

Local Institution, Seoul, Kangnam-gu

Local Institution, Seoul, Seodaemungu

Local Institution, Busan, Not set

Local Institution, Daegu, Not set

Local Institution, Gyeonggi-do, Not set

Local Institution, Seoul, Not set

Local Institution, Suwon, Not set

Local Institution, Mexico, Distrito Federal

Local Institution, Zapopan, Jalisco

Local Institution, Monterrey, Nuevo LEON

Local Institution, Breda, Not set

Local Institution, Harderwijk, Not set

Local Institution, Hertogenbosch, Not set

Local Institution, Nieuwegein, Not set

Local Institution, Trujillo, LA Libertad

Local Institution, Arequipa, Not set

Local Institution, Cercado, Not set

Local Institution, Lima, Not set

Local Institution, Elblag, Not set

Local Institution, Gdansk- Zaspa, Not set

Local Institution, Gdansk, Not set

Local Institution, Grudziadz, Not set

Local Institution, Olsztyn, Not set

Local Institution, Otwock, Not set

Local Institution, Poznan, Not set

Local Institution, Szczecin, Not set

Local Institution, Torun, Not set

Local Institution, Warsaw, Not set

Local Institution, Sao Martinho Do Bispo, Coimbra

Local Institution, Lisboa, Not set

Local Institution, Porto, Not set

Local Institution, Santa Maria Da Feira, Not set

Local Institution, Vila Nova De Gaia, Not set

Local Institution, Bucharest, Not set

Local Institution, Bucuresti, Not set

Local Institution, Cluj Napoca, Not set

Local Institution, Sibiu, Not set

Local Institution, Suceava, Not set

Local Institution, Timisoara, Not set

Local Institution, Chelyabinsk, Not set

Local Institution, Kazan, Not set

Local Institution, Moscow, Not set

Local Institution, Pyatigorsk, Not set

Local Institution, Saint Petersburg, Not set

Local Institution, St-Peterburg, Not set

Local Institution, St. Petersburg, Not set

Local Institution, Tula, Not set

Local Institution, Singapore, Not set

Local Institution, Vereeniging, Gauteng

Local Institution, Panorama,cape Town, Western CAPE

Local Institution, Cape Town, Not set

Local Institution, Durban, Not set

Local Institution, Barakaldo, Vizcaya

Local Institution, Avila, Not set

Local Institution, Benidorm-alicante, Not set

Local Institution, Castellon, Not set

Local Institution, Madrid, Not set

Local Institution, Manresa, Not set

Local Institution, Ourense, Not set

Local Institution, Valencia, Not set

Local Institution, Gothenburg, Not set

Local Institution, Lund, Not set

Local Institution, Stockholm, Not set

Local Institution, Umea, Not set

Local Institution, Basel, Not set

Local Institution, Winterthur, Not set

Local Institution, Changhua City, Not set

Local Institution, Chiayi, Not set

Local Institution, Kaohsiung County, Not set

Local Institution, Taichung, Not set

Local Institution, Taipei City, Not set

Local Institution, Taipei, Not set

Local Institution, Bangkok, Tungpayathai

Local Institution, Bangkok, Not set

Local Institution, Chiang Mai, Not set

Local Institution, Songkhla, Not set

Local Institution, Dundee, Angus/forfarshire

Local Institution, Truro, Cornwall

Local Institution, Southampton, Hampshire

Local Institution, Nottingham, Not set

Local Institution, Sheffield, Not set

Conditions: Lung Cancer - Non Small Cell Squamous

Learn More ›

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

NCT02514551

Completed

The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma (GEJ).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/10/2020

Locations: City of Hope National Medical Center, Duarte, California +51 locations

City of Hope National Medical Center, Duarte, California

University of Kansas Medical Center, Westwood, Kansas

Dana Farber Cancer Institute, Boston, Massachusetts

Montefiore Medical Center, Bronx, New York

Weill Cornell Medical College, New York, New York

Scott & White Memorial Hospital & Clinic, Temple, Texas

Vista Oncology Inc. PS, Olympia, Washington

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Not set

For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Calgary, Not set

Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Learn More ›

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

NCT01862328

Completed

The purpose of this study is to establish the maximum tolerated dose (MTD) and assess the safety and tolerability of MLN4924 (pevonedistat) in combination with docetaxel, paclitaxel and carboplatin, and gemcitabine in participants with solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/05/2020

Locations: Not set, Atlanta, Georgia +5 locations

Conditions: Solid Tumors

Learn More ›

Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer

NCT00617942

Completed

Q3week carboplatin with weekly abraxane and trastuzumab as neoadjuvant therapy in resectable and unresectable HER2+ (stage IIa-IIIb) breast cancer

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

05/28/2020

Locations: City of Hope, Duarte, California +4 locations

Conditions: Breast Cancer

Learn More ›

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

NCT01792050

Completed

The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy (docetaxel or paclitaxel) with or without the addition of 1-Methyl-D-tryptophan (referred to as indoximod) an experimental drug to find out which treatment is better.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/26/2020

Locations: University of Florida Health Cancer Center, Gainesville, Florida +39 locations

University of Florida Health Cancer Center, Gainesville, Florida

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Space Coast Cancer Center, Titusville, Florida

Cleveland Clinic - Florida, Weston, Florida

University Cancer & Blood Center, LLC, Athens, Georgia

Georgia Regents University, Augusta, Georgia

Illinois Cancer Specialists, Arlington Heights, Illinois

University of Illinois Cancer Center, Chicago, Illinois

Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Eastchester Center for Cancer Care, Bronx, New York

University of North Carolina, Chapel Hill, North Carolina

Wake Forest Baptist Hospital, Winston-Salem, North Carolina

Fairview Hospital, Cleveland, Ohio

Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio

Taussig Cancer Institute, Mayfield Heights, Ohio

Bryn Mawr Hospital, Bryn Mawr, Pennsylvania

Pennsylvania State University Milton S. Hershey Medical Center, Hershey, Pennsylvania

Paoli Hospital, Paoli, Pennsylvania

Lankenau Medical Center, Wynnewood, Pennsylvania

University of Tennessee Medical Center, Knoxville, Tennessee

MD Anderson Cancer Center, Houston, Texas

University of Virginia, Charlottesville, Virginia

Lynchburg Hematology Oncology, Lynchburg, Virginia

Peninsula Cancer Center, Newport News, Virginia

Virginia Commonwealth University, Richmond, Virginia

Wheaton Franciscan Healthcare- Reiman Cancer Center, Franklin, Wisconsin

Aurora Baycare, Green Bay, Wisconsin

Research SiteR, Brzozow, Not set

Reserach Site, Gdansk, Not set

Research Site, Gdynia, Not set

Research Site, Gorzow Wielkopolski, Not set

Reserach Site, Konin, Not set

Research Site, Krakow, Not set

Research Site, Olsztyn, Not set

Research Site, Poznan, Not set

Research Site, Rybnik, Not set

Research Site, Rzeszow, Not set

Research Site, Warsaw, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NCT01836432

Terminated

Unfortunately, despite the best clinical efforts and breakthroughs in biotechnology, most patients diagnosed with pancreatic cancer continue to die from the rapid progression of their disease. One primary reason for this is that the disease is typically without symptoms until significant local and/or distant spread has occurred and is often beyond the chance for cure at the time of the diagnosis. The lack of any treatment to substantially increase long term survival rates is reflected by the poor outcomes associated with this disease, specifically time to disease progression and overall survival. However, another important part of the body is now being looked at as a target for therapy against this disease - the immune system. Scientists have clearly shown that pancreatic tumor cells produce a number of defective proteins, or express normal proteins in highly uncharacteristic ways, as part of this cancer. In some cancers, these abnormalities can cause an immune response to the cancer cells much in the way one responds to infected tissue. In progressive cancers however, the immune system fails to effectively identify or respond to these abnormalities and the cancer cells are not attacked or destroyed for reasons not yet fully understood. This clinical trial proposes a new way to stimulate the immune system to recognize pancreatic cancer cells and to stimulate an immune response that destroys or blocks the growth of the cancer. This new method of treatment helps the immune system of pancreatic cancer patients to "identify" the cancerous tissue so that it can be eliminated from the body. As an example, most people are aware that patients with certain diseases may require an organ transplant to replace a damaged kidney or heart. After receiving their transplant, these patients receive special drugs because they are at great danger of having an immune response that destroys or "rejects" the transplanted organ. This "rejection" occurs when their immune system responds to differences between the cells of the transplanted organ and their own immune system by attacking the foreign tissue in the same way as it would attack infected tissue. When the differences between foreign tissues and the patient's body are even larger, as with the differences between organs from different species, the rejection is very rapid, highly destructive, and the immunity it generates is longlasting. This is called hyperacute rejection and the medicine used to immunize patients in this protocol tries to harness this response to teach a patient's immune system to fight their pancreatic cancer just as the body would learn to reject a transplanted organ from an animal. To do this, Algenpantucel-L immunotherapy contains human pancreatic cancer cells that contain a mouse gene that marks the cancer cells as foreign to patient's immune systems. The immune system therefore attacks these cancer cells just as they would attack any truly foreign tissue, destroying as much as it can. Additionally, the immune system is stimulated to identify differences (aside from the mouse gene) between these cancer cells and normal human tissue as foreign. This "education" of the immune system helps treat the patient because pancreatic cancer cells already present in a treated patient are believed to show some of the same differences from normal tissue as the modified pancreatic cancer cells in the product. Due to these similarities, the immune system, once "educated" by the Algenpantucel-L immunotherapy, identifies the patient's cancer as foreign and attacks. The chemotherapy combination to be used in this study has been shown to improve survival in advanced pancreatic cancer and is being combined with an experimental pancreatic cancer immunotherapy that stimulates the immune system to recognize and attack the cancer. One goal of this study is to determine whether chemotherapy and immunotherapies can work cooperatively to increase anti-tumor effects to levels beyond what would be seen with either treatment alone. In this experimental study, all patients are given a strong combination of anti-tumor chemotherapies while some patients are also given injections of an immunotherapy drug consisting of two types of pancreatic cancer cells that we have modified to make them more easily recognized and attacked by the immune system. We propose to test this new treatment protocol in patients with locally advanced pancreatic cancer to demonstrate that treatment with the immunotherapy increases the time until the tumor progresses or increases overall survival when given in combination with the current standard of care therapy for this disease. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/26/2020

Locations: Arizona Cancer Center, Tucson, Arizona +31 locations

Arizona Cancer Center, Tucson, Arizona

Cedars-Sinai Medical Center, Los Angeles, California

Sutter Institute for Medical Research, Sacramento, California

California Pacific Medical Center, San Francisco, California

Stamford Hospital, Stamford, Connecticut

Boca Raton Regional Hospital, Boca Raton, Florida

University of Florida, Gainesville, Florida

University of Miami, Miami, Florida

USF Tampa General, Tampa, Florida

H. Lee Moffitt Cancer Center, Tampa, Florida

Illinois Cancer Specialists, Arlington Heights, Illinois

Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana

Indiana University, Indianapolis, Indiana

University of Kansas Cancer Center, Westwood, Kansas

University of Louisville, Louisville, Kentucky

Beaumont CCOP, Royal Oak, Michigan

Virginia Piper Cancer Institute, Minneapolis, Minnesota

Renown Regional Medical Center, Reno, Nevada

Jersey Shore University Medical Center, Neptune, New Jersey

Mount Sinai Medical Center, New York, New York

Wake Forest Baptist Health, Winston-Salem, North Carolina

The Ohio State University, Columbus, Ohio

University of Oklahoma, Oklahoma City, Oklahoma

Oregon Health and Science University, Portland, Oregon

Thomas Jefferson University, Philadelphia, Pennsylvania

University of Tennessee Medical Center, Knoxville, Tennessee

University of Texas Southwestern Medical Center, Dallas, Texas

Baylor College of Medicine, Houston, Texas

University of Virginia, Charlottesville, Virginia

University of Washington - Seattle Cancer Center Alliance, Seattle, Washington

Vince Lombardi Cancer Center, Green Bay, Wisconsin

University of Wisconsin, Madison, Wisconsin

Conditions: Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm

Learn More ›

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

NCT02077881

Completed

This phase I/II trial is designed to efficiently identify the regimen limiting toxicity (RLT) and recommended phase 2 dose (RP2D) for the combination of the immunotherapeutic agent indoximod when administered in combination with standard of care chemotherapy gemcitabine plus nab-paclitaxel in subjects with metastatic adenocarcinoma of the pancreas. All subjects will receive the same standard gemcitabine plus nab-paclitaxel regimen, plus indoximod in doses increasing from 600 mg twice daily to, p... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/26/2020

Locations: Stanford University, Palo Alto, California +10 locations

Conditions: Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer

Learn More ›

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT02389985

Terminated

The purpose of this study is to estimate the maximum tolerated doses (MTD) of CRLX101 when administered in combination with weekly paclitaxel in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer. Determine through pharmacokinetic evaluation(sometimes described as what the body does to a drug, refers to the movement of drug into, through and out of the body-the time and course of its absorption, bioavailability, distribution, metabolism, and excr... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

05/26/2020

Locations: Massachusetts General Hospital, Boston, Massachusetts +6 locations

Conditions: Ovarian Cancer

Learn More ›

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

NCT01803282

Completed

The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with chemotherapy. The study consists of 2 parts (Parts A and B). Participants can only qualify for and participate in 1 part. Part A is a sequential dose escalation to determine the maximum tolerated dose of andecaliximab in participants with advanced solid tumors that are refractory... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/20/2020

Locations: Alabama Oncology, Birmingham, Alabama +17 locations

Conditions: Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer

Learn More ›

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT03704077

Withdrawn

The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/17/2020

Locations: Local Institution, Daphne, Alabama +83 locations

Local Institution, Daphne, Alabama

Local Institution, Bakersfield, California

Local Institution, Fullerton, California

Local Institution, Los Angeles, California

Local Institution, Redondo Beach, California

Local Institution, Santa Barbara, California

Local Institution, Aurora, Colorado

Local Institution, Lakewood, Colorado

Local Institution, Miami, Florida

Local Institution, Tampa, Florida

Local Institution, Marietta, Georgia

Local Institution, Boston, Massachusetts

Local Institution, Saint Louis, Missouri

Local Institution, New Brunswick, New Jersey

Local Institution, Chapel Hill, North Carolina

Local Institution, Charlotte, North Carolina

Local Institution, Fargo, North Dakota

Local Institution, Allentown, Pennsylvania

Local Institution, Sioux Falls, South Dakota

Local Institution, Vancouver, Washington

Local Institution, Viedma, RIO Negro

Local Institution, Buenos Aires, Not set

Local Institution, Caba, Not set

Local Institution, Ciudad Autonoma de Buenos Aires, Not set

Local Institution, Cordoba, Not set

Local Institution, Westmead, New South Wales

Local Institution, Heidelberg, Victoria

Local Institution, Malvern, Victoria

Local Institution, Melbourne, Victoria

Local Institution, Bedford Park, Not set

Local Institution, Murdoch, Not set

Local Institution, Fortaleza, Ceara

Local Institution, Belo Horizonte, Minas Gerais

Local Institution, Porto Alegre, RIO Grande DO SUL

Local Institution, Barretos, SAO Paulo

Local Institution, Jau, SAO Paulo

Local Institution, Rio de Janeiro, Not set

Local Institution, Sao Paulo, Not set

Local Institution, Halifax, Nova Scotia

Local Institution, Hamilton, Ontario

Local Institution, Ottawa, Ontario

Local Institution, Toronto, Ontario

Local Institution, Montreal, Quebec

Local Institution, Sherbrooke, Quebec

Local Institution, Santiago, Metropolitana

Local Institution, Medellin, Not set

Local Institution, Berlin, Not set

Local Institution, Cologne, Not set

Local Institution, Erlangen, Not set

Local Institution, Essen, Not set

Local Institution, Frankfurt am Main, Not set

Local Institution, Freiburg, Not set

Local Institution, Hamburg, Not set

Local Institution, Hannover, Not set

Local Institution, Jena, Not set

Local Institution, Mainz, Not set

Local Institution, Mannheim, Not set

Local Institution, Marburg, Not set

Local Institution, Paderborn, Not set

Local Institution, Reutlingen, Not set

Local Institution, Wiesbaden, Not set

Local Institution, Bergamo, Not set

Local Institution, Milano, Not set

Local Institution, Napoli, Not set

Local Institution, Reggio Emilia, Not set

Local Institution, Tuxtla Gutierrez, Chiapas

Local Institution, Mexico City, Distrito Federal

Local Institution, ZONA Centro. LEON, Guanajuato

Local Institution, Merida, Yucatan

Local Institution, Aguascalientes, Not set

Local Institution, Lisboa, Not set

Local Institution, Porto, Not set

Local Institution, Rio Piedras, Not set

Local Institution, Bucuresti, Not set

Local Institution, Cluj-Napoca, Not set

Local Institution, Craiova, Not set

Local Institution, Floresti, Not set

Local Institution, Badajoz, Not set

Local Institution, Madrid, Not set

Local Institution, Valencia, Not set

Conditions: Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction

Learn More ›

Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence

NCT00915005

Completed

The goal of this clinical research study is to learn if, compared with regular x-ray radiation, proton radiation reduces the risk of developing, treatment-related pneumonitis (TRP) or tumor recurrence (the tumor coming back in the irradiated area after treatment) in patients with lung cancer.

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

05/07/2020

Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations

Conditions: Non-Small-Cell Lung Carcinoma

Learn More ›

Browse by State

Paclitaxel treatment options in Alabama

Paclitaxel treatment options in Alaska

Paclitaxel treatment options in Arizona

Paclitaxel treatment options in Arkansas

Paclitaxel treatment options in California

Paclitaxel treatment options in Colorado

Paclitaxel treatment options in Connecticut

Paclitaxel treatment options in Delaware

Paclitaxel treatment options in District of Columbia

Paclitaxel treatment options in Florida

Paclitaxel treatment options in Georgia

Paclitaxel treatment options in Hawaii

Paclitaxel treatment options in Idaho

Paclitaxel treatment options in Illinois

Paclitaxel treatment options in Indiana

Paclitaxel treatment options in Iowa

Paclitaxel treatment options in Kansas

Paclitaxel treatment options in Kentucky

Paclitaxel treatment options in Louisiana

Paclitaxel treatment options in Maine

Paclitaxel treatment options in Montana

Paclitaxel treatment options in Nebraska

Paclitaxel treatment options in Nevada

Paclitaxel treatment options in New Hampshire

Paclitaxel treatment options in New Jersey

Paclitaxel treatment options in New Mexico

Paclitaxel treatment options in New York

Paclitaxel treatment options in North Carolina

Paclitaxel treatment options in North Dakota

Paclitaxel treatment options in Ohio

Paclitaxel treatment options in Oklahoma

Paclitaxel treatment options in Oregon

Paclitaxel treatment options in Maryland

Paclitaxel treatment options in Massachusetts

Paclitaxel treatment options in Michigan

Paclitaxel treatment options in Minnesota

Paclitaxel treatment options in Mississippi

Paclitaxel treatment options in Missouri

Paclitaxel treatment options in Pennsylvania

Paclitaxel treatment options in Rhode Island

Paclitaxel treatment options in South Carolina

Paclitaxel treatment options in South Dakota

Paclitaxel treatment options in Tennessee

Paclitaxel treatment options in Texas

Paclitaxel treatment options in Utah

Paclitaxel treatment options in Vermont

Paclitaxel treatment options in Virginia

Paclitaxel treatment options in Washington

Paclitaxel treatment options in West Virginia

Paclitaxel treatment options in Wisconsin

Paclitaxel treatment options in Wyoming